MS4A6E

Across TCGA pan-cancer cohorts, MS4A6E Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MS4A6E data layer compared with 15 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MS4A6E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MS4A6E expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, LGG, and UCEC are the cancer types where MS4A6E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	28	view →
LGG	OS	Median	All	0.195	0.896	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	1.000	0.777	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MS4A6E–LUAD (OS)

Open the LUAD breakdown →